Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — What the Future Holds for Hemp-Sourced Cannabinoids

In the early 1970s, the federal government outlawed all cannabis cultivation, and failing to distinguish between hemp and its psychoactive cousin cannabis, declared it illegal to cultivate both cannabis and hemp. These policies held for decades, and while the illicit market continued supplying cannabis, hemp nearly faded into obscurity. In 2014, Congress passed a farm bill that allowed state agriculture departments and universities to grow hemp in pilot programs as long as their home states permitted it.

Four years later, the 2018 farm gill removed hemp from the list of controlled substances, allowing the cultivation, processing and sale of hemp and hemp derivatives. Just a few years later, America’s young hemp industry has blossomed, partly driven by the explosive demand for cannabinoids, CBD in particular.

Cannabinoids are chemical compounds produced by plants of the cannabis sativa species, which includes hemp and cannabis. Hemp has less than 0.3% THC, the main psychoactive compound in cannabis, hence hemp products will not intoxicate you.

Said to be filled with potent medicinal properties, CBD has made hemp extremely valuable. The CBD pace has advanced rather quickly, and some have called the industry a Wild West where hype has far outpaced science. Consequently, the FDA has warned several companies against marketing CBD products as over the counter medicines and raised concerns about adding CBD to ingestible products such as foods, beverages, and dietary supplements. Still, nearly every states has passed some form of hemp legislation and allows the use of hemp and its derivatives in a variety of consumer products, including ingestible products and pet products.

Other minor cannabinoids, including cannabigerol (“CBG”), delta-8 THC and cannabinol (“CBN”), have been subject to increasing attention. However, these minor cannabinoids are relatively unknown and make up a very small segment of the hemp industry. They still have plenty of regulatory hurdles to clear, let alone gaining the high level of market visibility that CBD has achieved within the past five years. Since these minor cannabinoids have barely been subject to scientific research and clinical studies, policymakers still do not understand them or what they can do.

In fact, we do not know a lot about most of the approximately 100 cannabinoids hemp produces. But based on how cannabidiol fared, we can assume that these cannabinoids will also go through a similar process. Increasing popularity will attract more sellers to the market, plenty of them unscrupulous. We may even see companies advertising these cannabinoids as miracle cures for certain diseases, much like some companies have done with CBD. However, the FDA has been quick to shut down such claims and offer guidance on CBD, and we can assume the federal agency will do the same with the larger hemp-sourced cannabinoid sector.

Sellers are constantly coming up with new CBD products, forcing federal and regulators to constantly redefine what is legal and what isn’t. Some states may allow cannabinoid-infused transdermal patches and CBD flower while others may not. Meanwhile, the FDA will continue to provide guidance on cannabinoids and how they can and cannot be used in the absence of a federal comprehensive regulatory structure.

At the moment, cannabis companies that are interested in different cannabinoids, such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), are working within the existing regulatory framework to manufacture premium products aimed at addressing the needs of their customers.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Patients with High-Grade Gliomas Register Improved Quality of Life after Using Medical Marijuana

The past few decades have seen cannabis progress from an intensely policed drug with no perceived medical applications to a “miracle drug” with a plethora of health benefits. Anecdotal reports and preliminary studies have found it to be effective against, among other things, chronic pain, anxiety insomnia, nausea and vomiting, which are incidentally the symptoms often endured by individuals suffering from cancer who are undergoing chemotherapy. Thanks to restrictive cannabis policies, few researchers have been able to conclusively study how cannabis affects the quality of life of cancer patients.

However, a recent study published in “Frontiers in Oncology” sought to answer this question in the midst of loosening cannabis restrictions. Researchers conducted a randomized, phase 2 trial that compared the effect of two different ratios of oral medical cannabis oil in patients with inoperable or recurrent gliomas. They discovered that a nightly dose of medical marijuana led to improved symptoms that determine quality of life, such as sleep.

The study, which is one of the few of its kind, had 88 participating patients with the average age of 53.3 years. Most of the patients (95.2%) were white with approximately one- half of them (49.4%) being women. The patients randomly received medical cannabis with either 1:1 ratio of THC to CBD (4.6 mg/ml:4.8 mg/ml) or a 4:1 ratio of THC to CBD (15 mg/ml:3.8mg/ml).The researchers then used a paired t-test for the Functional Assessment of Cancer Therapy-Brain (FACT-Br) to study quality of life changes from week 1 to week 12.

Fifty-three patients also had MRIs at the start of the study and at week 12 to determine disease status. The researchers found that the daily dose of medical cannabis resulted in significant improvements in the physical and functional domains as well as sleep with the 1:1 medical cannabis being more effective that the 4:1 ratio. However, there was no significant difference between the two ratios in terms of disease status: 11% of the 53 patients experienced a reduction in disease status, 34% remained stable and 10% had progressive disease.

While there is usually a risk of adverse reactions with such studies, the researchers say the participants tolerated both medical cannabis ratios quite well. Still, they did experience the common side effects of cannabis consumption; drowsiness (7%), dizziness at night (10%), tiredness at night (11%) and dry mouth (13%). The researchers concluded that based on their data, cannabis, especially the 1:1 THC to CBD ratio, could help patients with high grade gliomas have a higher quality of life.

THC and CBD are the most abundant of the cannabinoids in marijuana, but the plant actually contains dozens more, and companies such as InMed Pharmaceuticals Inc. (NASDAQ: INM) are focused on unlocking the therapeutic benefits of those lesser-known cannabinoids such as CBN, which have proved in preliminary research to possess greater potential as medicines when compared to CBD and THC.

NOTE TO INVESTORS: The latest news and updates relating to InMed Pharmaceuticals Inc. (NASDAQ: INM) are available in the company’s newsroom at https://cnw.fm/INM

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Why Investors Interested in Cannabis Should Expect a Big Stock Surge

At the moment, more than 100 million residents in the United States live in a state that has legalized recreational cannabis, with a whopping 95% living in a state with a legal medical cannabis system in place. Cannabis multistate operators are readying themselves for the next huge stock increase, which is expected to happen even without a change in federal legislations.

Marijuana is fast closing the revenue gap, especially with the emergence of profitability, after the huge infrastructure spending that began in 2018 and 2019. Trading indexes show favorable valuations throughout this season, despite the imminent federal legislative gridlock.

Marijuana revenues in the United States increased significantly between 2014 and 2020, moving from $1.9 billion to $17.5 billion, even without the enactment of federal legislations such as the SAFE Banking Act. Recent forecasts from “Forbes” show that by 2025, the U.S. marijuana market will have reached $43 billion, which is quite a jump from the $29 billion prediction from a few months ago.

With more states across the country legalizing the herb for recreational and/or medicinal use, 2021 is set to be a good year, with the cannabis market expected to see an even larger increase in the coming year. Additionally, as more demographics such as seniors get on board with marijuana therapies, the industry expands faster and grows even stronger.

The quality of companies now operating in the marijuana market is considerably different from companies that were operating in the market in 2015 when the U.S. Marijuana Index begun. Small companies are now focused on profit making, which entails starving multistate operators of capital markets with profitability also being the main objective of larger and better-developed multistate operators.

Infrastructure building as well as mergers and acquisitions have also increased substantially, with both global and U.S. capital markets responding to this by increasing their cannabis services. The United States is receiving the biggest benefit of private equity financing because of the increased fundamentals of cannabis companies and the huge revenue stream that’s gaining momentum.

Whether we like it or not, the profitability model brought by marijuana federal legalization in Canada is here to stay. Despite most monies being injected into companies in the United States, investing in profitable operations is still the main aim, especially as infrastructure and M&A investments are expected to increase annually in this particular market.

Until federal regulations catch up to consumer preferences, marijuana sales will continue increasing, more states will legalize the herb, and companies will continue to hit record highs.

When you see industry players such as Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) report nearly 200 people on their payroll, it appears to be a clear sign that the sector is growing and things are likely to keep looking up for years to come.

NOTE TO INVESTORS: The latest news and updates relating to Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) are available in the company’s newsroom at https://cnw.fm/CHALF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) to Host 1H 2021 Earnings Call

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that it will host its first-half 2021 earnings call following the release of its first-half 2021 financial results. The webcast is scheduled to be held at 4:30 p.m. ET on Thursday, Aug. 19, 2021. FLGC management will deliver financial results, operational updates, as well as provide comments on recent growth and M&A initiatives announced in the period since the company listed its shares on the Nasdaq Capital Market on May 11, 2021. Following the presentation, Flora will offer analysts, media and investors the opportunity to ask questions in a question-and-answer session. Interested parties may join the live webcast by visiting https://cnw.fm/89ocu. In addition, a replay of the call will be available until Sept. 3, 2021, by dialing 1-844-512-2921 (Canada/USA) or 1-412-317-6671 (international) and entering access code: 13722364.

To view the full press release, visit https://cnw.fm/O1tbc

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals

Lexaria Bioscience Corp. (NASDAQ: LEXX) is constantly collaborating with research institutions and businesses to identify new ways to innovate and improve its DehydraTECH(TM) drug-delivery technology. DehydraTECH is already being monetized through commercial use, and the company is utilizing advanced 2.0 formulations in ongoing human studies. A recent article discusses Lexaria’s move to consolidate the trading of its shares solely on the Nasdaq, and resulting advantages to the company and its shareholders. “Since it was listed back in January 2021, a substantial fraction of its shareholders moved onto this exchange. To them, it offered more liquidity than ever before, and to Lexaria, it presented an opportunity to realize savings in fees and managerial time,” the article reads. “The company’s management intends to direct the cost savings resulting from this move to its applied research and development programs, which would further advance the company’s business. Just earlier this year, Lexaria’s HYPER-A21-1 study resulted in the inclusion of three new DehydraTECH 2.0 formulation variations that would enable cannabidiol (‘CBD’) delivery performance enhancements as well as pharmacokinetic optimization. With more funding for such research, Lexaria is well-positioned to achieve even better results and better outcomes for its drug-delivery goals.”

To view the full article, visit https://cnw.fm/1Hr3A

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes. It is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Green Hygienics Holdings Inc. (GRYN) Stands Distinct in Industrial Hemp Sector

Green Hygienics Holdings (OTCQB: GRYN) is enhancing its corporate responsibility and sustainability goals to empower environmental progress. The company plans to incorporate systemic environmental, social and governance (“ESG”) factors into business planning aimed at serving the needs of investors and stakeholders who value the importance of ESG reporting. “With the help of KERAMIDA Inc., a premier sustainability consulting firm, Green Hygienics is developing an ESG report using the Sustainability Accounting Standards Board (‘SASB’), maintained by the Value Reporting Foundation. Sustainability and ESG are an integral part of the company’s value system,” reads a recent article. Green Hygienics is the first industrial hemp company to undertake an ESG report, reflecting a proactive approach to move ahead of future government mandates. Developing an ESG report and following through on its guidelines is likely to further cement Green Hygienics’ position in the market, as well as influence positive investor interest and growth opportunities.

To view the full article, visit https://cnw.fm/LSJx6

About Green Hygienics Holdings Inc.

Green Hygienics Holdings is a California-based, innovative, technology-driven enterprise focused on the high-standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids. The company’s corporate mission is to adhere to the highest standards of operations in consistently delivering safe and premium-quality products to consumers as well as to partner with CPG (consumer packaged goods) and pharmaceutical companies. Hygienics is the science of preserving and promoting the health of individuals, communities and the planet. For more information about the company, visit www.GreenHygienics.com.

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://cnw.fm/GRYN

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — California Senator Asks Feds to Clarify Medical Cannabis Use Within Hospitals

The state legal cannabis industry can be a frustrating and confusing space. Despite the fact that more than 30 states have legalized medical marijuana, federal law still considers cannabis a Schedule I controlled substance with no medical applications. So while on one end nearly 5.5 million patients are using medical cannabis to alleviate a variety of medical issues, the federal government outlaws the controversial drug and requires federal agencies and institutions that rely on federal funding to follow its marijuana policies.

This has been a significant issue for the past few years, with businesses and individuals finding themselves penalized by the federal government for acts that are considered legal in their home states. In fact, this confusion led California Gov. Gavin Newsom to veto a bill that would have allowed health institutions to allow cannabis use as he was under the impression that this would jeopardize their federal funding.

In that vein, a California senator has sent a request asking the head of the U.S. Department of Health and Human Services (“HHS”) to clarify whether hospitals and healthcare institutions in states with legal marijuana markets can allow terminally ill patients to use medical cannabis without risking their federal funding. Since the federally funded institutions are required to abide by federal policies, it makes sense that healthcare institutions would be wary of recommending medical marijuana to their patients.

Sent by Senator Ben Huesco to HHS Secretary Xavier Becerra and Centers of Medicare and Medicaid Services (“CMS”) Administrator Chiquita Brooks LaSure, the letter asks the federal officials to lay out the possible implications if health facilities start permitting marijuana consumption. Senator Huesco has also filed an almost identical version of the bill, which has already advanced in the Senate as well as one Assembly committee and is now pending action on the Assembly floor.

Dubbed Ryan’s Law, the legislation would require hospitals and some healthcare facilities in California to allow terminally ill patients to use medical cannabis for treatment and pain relief. While hospitals that receive CMS accreditation currently do not allow this due to fear of federal reprisals, Huesco says a letter sent to his office by the CMS states no federal regulations specifically address this issue, and the agency isn’t aware of any hospital that has had its funding pulled due to medical marijuana.

Still, most hospitals, and even lawmakers, have been under the impression that hospitals couldn’t allow medical cannabis use, the letter notes. As such, providing clarification on whether or not Medicare/Medicaid providers will lose federal reimbursement for allowing medical cannabis on site would be significantly helpful to the patients who need medical cannabis and hospitals.

If the clarification is provided that patients can use medical marijuana in hospitals located in states with medical cannabis laws, one of the many ambiguities that the entire cannabis industry, including Sonoma Biologics Corp., faces would have been removed.

NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Finds That Patients with Epilepsy Who Use CBD Have Higher Quality of Life

A recent study has found that patients with epilepsy who use CBD products experienced better sleep and a higher quality of life in comparison with those who didn’t take CBD. The study, which was carried out in partnership with scientists at the Johns Hopkins University School of Medicine, was published in the “Epilepsy & Behavior” journal.

The study discovered that epilepsy patients who used cannabinoid products also experienced less psychiatric symptoms, including anxiety, used fewer prescription medications generally and tolerated medications prescribed for epilepsy better. They also reported decreased healthcare use in comparison with patients in the control group.

The authors of the study noted that while no substantial differences in seizure control were observed between patients who didn’t use CBD and those who did, both groups had individuals who hadn’t suffered seizures in the past month.

In their report, the researchers stated that their findings highlighted the need for controlled research to ascertain optimal CBD doses, product types and associated use of other medications that would minimize potential risks and maximize clinical benefit of the cannabinoid’s use.

The study centered on alternatives to Epidiolex, which is the pharmaceutical-grade CBD oil product that the FDA approved to treat specific types of epilepsy in 2018. The researchers explained that prescription CBD was a restricted medication, noting that insurance coverage was often limited to patients who suffered from the approved indications, which is why most patients who suffer from epilepsy chose to use alternative CBD products that are sold by commercial vendors as dietary supplements.

For the study, the researchers conducted an analysis of survey results from nearly 300 patients who suffer from epilepsy and admitted to using artisanal CBD products and about 140 patients who revealed that they did not use any marijuana products. The study’s participants were recruited using social media posts and patient registries provided by the Realm of Caring Foundation, with follow-up surveys being conducted on 190 participants.

Nearly 75% of the patients who took part in the survey were white, with more than 50% of them being female. About 90% of the participants revealed that they had no history of recreational or nonmedical marijuana use. Additionally, more than 90% of the participants reported epilepsy as their main condition, with the remainder revealing that they developed epilepsy related to sleep disorders, neuropsychiatric or autoimmune conditions, cancer and other conditions.

The study was financed by a not-for-profit foundation devoted to CBD therapies, known as the Realm of Caring Foundation.

This study is yet another indication that people who use the CBD products made by cannabis companies such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) may obtain sme relief from certain symptoms that they suffer from.

NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Alkaline88’s Aluminum Bottle Offering Available in 9,000+ Stores

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has announced that  Alkaline88(TM), the company’s flagship product, offered in eco-friendly, fully recyclable 16-ounce aluminum bottles, is now available in more than 9,000 stores around the country. According to the announcement, the company noted that the number of stores carrying the aluminum bottle offering has grown more than 300% in the past three months alone. The proprietary product is carried by leading grocery chains such as Albertsons, Sprouts Farmers Market, Meijer, H-E-B and Harris Teeter as well as numerous independent grocers. Alkaline88 is known for its superior hydration with a perfect 8.8pH balance. WTER, the country’s largest independent alkaline water company and the Clean Beverage Company(TM), produces premium bottled alkaline water, flavor-infused waters and CBD-infused products sold under the brand names Alkaline88(R), A88 Infused(TM) and A88CBD(TM). “Sales of our entire line of single serves continue to grow,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “Having our aluminum bottle available in 9,000 stores nationwide is incredible. We are seeing great growth and product acceptance where the aluminum bottle is currently available. We’re already the number-one, best-selling aluminum alkaline water for some of our major clients. Just three short months ago, I shared that our new etched-white aluminum bottle was in 2,700 retail locations, and since then, its store count presence has increased by over 330%. Consumers are quickly discovering just how refreshing and enjoyable it is to drink Deliciously Smooth(TM) Alkaline88from our ice-cold aluminum bottle. The future looks bright for our eco-friendly aluminum bottle. Through our distribution and brokerage partnerships including Natural Distributors, KeHE and UNFI, we now have reach into over 75,000 independent, regional and national retail grocery locations. With more of them currently reviewing our aluminum bottle for their next resets, we anticipate significant retail expansion for the product this year.”

To view the full press release, visit https://cnw.fm/bTxvI

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked Clean Beverage label. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes the company’s lab-tested, hemp-extract salves, balms, lotions, essential oils, bath salts, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Hero Technologies Inc. (HENC) Plans Expansion Leveraging Subsidiaries, Strategic Business Model

Hero Technologies (OTC: HENC) is guided by a strategic business plan that includes cannabis genetic engineering, cultivation space for both medical and recreational cannabis, licenses for production and distribution, consumer packaging, and retail and dispensary operations. “The company is planning expansion in cultivation and dispensary operations into both Colorado, through its wholly owned subsidiary Mile High Green LLC, and Massachusetts, through wholly owned subsidiary MassCannabis LLC,” reads a recent article. Its wholly owned subsidiary, BlackBox Systems and Technologies, which intends to install Cere’s EcoLoop(TM) — a high-tech, low-cost solution for growing cannabis — on its 120-acre property in Fairfield, Michigan, is also eying expansion. “BlackBox is in the process of expanding its Michigan operations. The company plans to break ground on 10 acres in September, with the construction of a 27,000-square-foot facility scheduled for completion next year. The new acreage will support four new greenhouses, with 12 more greenhouses in the planning stages.”

To view the full article, visit https://cnw.fm/ZTFXt

About Hero Technologies Inc.

Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. Hero Technologies’ strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator (“MSO”). For more information about the company, visit www.HeroTechnologiesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://cnw.fm/HENC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.